<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="JVirology Journal1743-422XBioMed CentralLondon pmcid: 72361111340 doi: 10.1186/s12985-020-01340-y : Research Human" exact="immunodeficiency" post="virus is a driven factor of human papilloma virus"/>
 <result pre="Research Human immunodeficiency virus is a driven factor of human" exact="papilloma" post="virus among women: evidence from a cross-sectional analysis in"/>
 <result pre="grid.442755.50000 0001 2168 3603School of Health Sciences, Catholic University of" exact="Central" post="Africa, [3], grid.412661.60000 0001 2173 8504University of Yaoundé I,"/>
 <result pre="occur in developing countries with an increasing risk associated to" exact="HIV infection." post="This study aimed at comparing HPV’s positivity and genotype"/>
 <result pre="Reference Centre (CIRCB) among 278 women enrolled consecutively at the" exact="General" post="Hospital and the Gynaeco-Obstetric and Paediatric Hospital of the"/>
 <result pre="algorithm, CD4 T cell phenotyping by flow cytometry and HIV" exact="viral" post="load by Abbott m2000RT. Statistical analyses were performed using"/>
 <result pre="genotypes other than 16 and 18. In the event of" exact="HIV infection," post="the risk of HPV positivity is two times higher,"/>
 <result pre="women should be closely monitored to prevent the emergence of" exact="cervical cancer." post="Keywords HPV HIV Women Yaoundé Background Human papilloma viruses"/>
 <result pre="of cervical cancer. Keywords HPV HIV Women Yaoundé Background Human" exact="papilloma" post="viruses (HPV) are non-enveloped DNA viruses that represent the"/>
 <result pre="non-enveloped DNA viruses that represent the most widespread sexually transmitted" exact="infection" post="worldwide, with more than 200 species. HPV genotypes are"/>
 <result pre="HPV genotypes are responsible for 95% of the occurrence of" exact="cervical cancer" post="in women [1]. Notably, HPV causes benign and malignant"/>
 <result pre="genotypes are responsible for 95% of the occurrence of cervical" exact="cancer" post="in women [1]. Notably, HPV causes benign and malignant"/>
 <result pre="occurrence of cervical cancer in women [1]. Notably, HPV causes" exact="benign" post="and malignant tumours in humans and viral genotypes that"/>
 <result pre="cervical cancer in women [1]. Notably, HPV causes benign and" exact="malignant" post="tumours in humans and viral genotypes that are oncogenic"/>
 <result pre="cancer in women [1]. Notably, HPV causes benign and malignant" exact="tumours" post="in humans and viral genotypes that are oncogenic are"/>
 <result pre="Notably, HPV causes benign and malignant tumours in humans and" exact="viral" post="genotypes that are oncogenic are classified as high-risk (HR-HPV)"/>
 <result pre="among the ten most commonly isolated HR-HPV genotypes from cervical" exact="tumor" post="biopsies [3, 4]. Indeed, cervical cancer is known to"/>
 <result pre="isolated HR-HPV genotypes from cervical tumor biopsies [3, 4]. Indeed," exact="cervical cancer" post="is known to be a viro-induced neoplasm and that"/>
 <result pre="HR-HPV genotypes from cervical tumor biopsies [3, 4]. Indeed, cervical" exact="cancer" post="is known to be a viro-induced neoplasm and that"/>
 <result pre="4]. Indeed, cervical cancer is known to be a viro-induced" exact="neoplasm" post="and that HPV is the causal agent in 99%"/>
 <result pre="of cases [4]. According to the World Health Organization (WHO)," exact="cervical cancer" post="will kill more than 443,000 people worldwide each year"/>
 <result pre="cases [4]. According to the World Health Organization (WHO), cervical" exact="cancer" post="will kill more than 443,000 people worldwide each year"/>
 <result pre="and other risk factors further increase the burden of this" exact="cancer" post="[5, 6]. In SSA, HPV and HIV co-infection is"/>
 <result pre="HIV co-infection is commonly found and contributes to a rapid" exact="disease" post="progression toward cervical cancer [4]. Importantly, HIV-positive women, especially"/>
 <result pre="commonly found and contributes to a rapid disease progression toward" exact="cervical cancer" post="[4]. Importantly, HIV-positive women, especially those who are severely"/>
 <result pre="found and contributes to a rapid disease progression toward cervical" exact="cancer" post="[4]. Importantly, HIV-positive women, especially those who are severely"/>
 <result pre="to a rapid disease progression toward cervical cancer [4]. Importantly," exact="HIV-positive" post="women, especially those who are severely immunocompromised, are 5"/>
 <result pre="severely immunocompromised, are 5 times more likely to develop the" exact="cervical cancer" post="than their HIV-negative peers. Even though little is known"/>
 <result pre="immunocompromised, are 5 times more likely to develop the cervical" exact="cancer" post="than their HIV-negative peers. Even though little is known"/>
 <result pre="(PLHIV) are still unclear [7]. Of note, Generally 66% of" exact="infections" post="are cleared at 12 months and this increases to 90%"/>
 <result pre="at 24 months [8]. For 10% of HPV-infected individuals, there is" exact="viral" post="persistence that remains at latency. In this frame, immunodeficiency"/>
 <result pre="is viral persistence that remains at latency. In this frame," exact="immunodeficiency" post="may be the cause of viral persistence and reactivation"/>
 <result pre="latency. In this frame, immunodeficiency may be the cause of" exact="viral" post="persistence and reactivation subsequently [7, 9]. Factors that contribute"/>
 <result pre="and reactivation subsequently [7, 9]. Factors that contribute to HPV" exact="infections" post="include: early sexual activity, multiple sexual partners, smoking, prolonged"/>
 <result pre="prolonged oral contraception and immuno-compromission (due to HIV essentially) [9]." exact="HIV infection" post="also promotes HPV infection at molecular and cellular levels"/>
 <result pre="oral contraception and immuno-compromission (due to HIV essentially) [9]. HIV" exact="infection" post="also promotes HPV infection at molecular and cellular levels"/>
 <result pre="(due to HIV essentially) [9]. HIV infection also promotes HPV" exact="infection" post="at molecular and cellular levels during different phases of"/>
 <result pre="(22.9%) [12]. In Cameroon, out of 14,000 new cases of" exact="cancer" post="reported in 2016, cervical cancer occupied the second leading"/>
 <result pre="out of 14,000 new cases of cancer reported in 2016," exact="cervical cancer" post="occupied the second leading position of cancers among women"/>
 <result pre="of 14,000 new cases of cancer reported in 2016, cervical" exact="cancer" post="occupied the second leading position of cancers among women"/>
 <result pre="cross-sectional study was carried-out in 2012 from women attending the" exact="General" post="Hospital and the Gyneco-obstetrical Hospital, both located in Yaoundé,"/>
 <result pre="samples were collected. HIV screening tests, CD4 lymphocyte counts, HIV" exact="viral" post="load, and HPV genotyping were performed at the Chantal"/>
 <result pre="at the Chantal BIYA International Reference Centre for research on" exact="HIV/AIDS" post="prevention and management (CIRCB) in Yaoundé, Cameroon (http://circb.cm/btc_circb/web/). Briefly,"/>
 <result pre="is a reference centre for HIV/AIDS, performing laboratory analysis with" exact="external" post="quality controls and proficiency testing for HIV screening (CDC"/>
 <result pre="DTS), HIV early infant diagnosis (CDC PT program), CD4 and" exact="viral" post="load (QASI, Canada). Sampling strategy Following a consecutive non-probabilistic"/>
 <result pre="study. However, pregnant women or those who had undergone a" exact="total" post="hysterectomy were not considered for inclusion. After consenting, a"/>
 <result pre="a serial algorithm as per the national guidelines, plasma HIV-1" exact="viral" post="load (solely for HIV+ cases) was done using the"/>
 <result pre="genotyping, the Abbott Real Time HR-HPV test was used. Briefly," exact="viral" post="DNA was extracted and amplified using the Abbott real-time"/>
 <result pre="Results Sociodemographic and bioclinical characteristics of the study population A" exact="total" post="of 278 eligible women were enrolled as participants in"/>
 <result pre="count was 399 cells/mm3. According to HIV-serostatus, median CD4 was" exact="lower" post="(354 [231–530 cells] cells/mm3) among HIV-seropositive women as compared"/>
 <result pre="to HIV serostatus HPVHIV HPV +n (%) HPV –n (%)" exact="Total" post="P-value HIV+ 80 (43.47) 104 (56.53) 184 HIV- 27"/>
 <result pre="104 (56.53) 184 HIV- 27 (28.42) 67 (70.53) 95 0.019" exact="Total" post="107 (38.49) 171 (61.51) 278 HPV human papillomavirus, HIV"/>
 <result pre="107 (38.49) 171 (61.51) 278 HPV human papillomavirus, HIV human" exact="immunodeficiency" post="virus Diversity of HPV genotypes in infected women Several"/>
 <result pre="HPV positivity by age HPVAge (years) HPV+n (%) HPV-n (%)" exact="Total" post="P-value 20–29 31 (51.66) 29 (48.33) 60 Ref 30–39"/>
 <result pre="(75.00) 64 0.03 50–75 11 (30.55) 25 (69.44) 36 0.64" exact="Total" post="107 (38.49) 171 (61.51) 278 HPV human papillomavirus, Age"/>
 <result pre="Marital Status HPVMarital status HPV +n (%) HPV –n (%)" exact="Total" post="P-value Single 63 (43.75) 81 (56.25) 144 Ref Married"/>
 <result pre="(40.00) 5 0.04 Widow 10 (35.71) 18 (64.29) 28 0.55" exact="Total" post="107 (38.49) 171 (61.51) 278 0.32 HPV human papillomavirus,"/>
 <result pre="a normal immunity (62.88% versus 35.71% respectively, p = 0.046). Interestingly, the" exact="lower" post="the CD4-count, the higher the rate of HPV positivity"/>
 <result pre="immune status HPVCD4 (cells/mm3) HPV +n (%) HPV –n (%)" exact="Total" post="P-value 500–1600 20 (35.71) 36 (64.29) 56 Ref 350–499"/>
 <result pre="(42.31) 26 0.844 &amp;lt; 200 20 (83.33) 4 (16.67) 24 0.048" exact="Total" post="81 (52.94) 72 (47.05) 153 Overall, HPV positivy seemingly"/>
 <result pre="153 Overall, HPV positivy seemingly increased with increasing values of" exact="viral" post="loads. 42.71% (41/96) with &amp;lt; 1000 RNA copies/ml vs. 66.00%"/>
 <result pre="by HIV viremia HPVHIV viremia(Log copies/mL) HPV+n (%) HPV-n (%)" exact="Total" post="P-value Undetectable (&amp;lt; 1.60) 25 (39.68) 38 (60.31) 63 Ref"/>
 <result pre="51 0.34 ≥ 3.00 38 (64.40) 21 (35.59) 59 0.12" exact="Total" post="88 (50.88) 85 (49.13) 173 HPV Human papillomavirus, viremia"/>
 <result pre="(49.13) 173 HPV Human papillomavirus, viremia different variation of HIV" exact="viral" post="load After adjusting for CD4, viral load and HIV"/>
 <result pre="different variation of HIV viral load After adjusting for CD4," exact="viral" post="load and HIV status, only HIV-infection was 12 times"/>
 <result pre="0.1109 2.5487 0.4295 HIV status 12.5000 4.0000 39.3000 &amp;lt; 0.0001 VL" exact="viral" post="load of HIV Discussion The purpose of our study"/>
 <result pre="study was to compare the rate of HPV positivity among" exact="HIV-positive" post="women with that of HIV-negative women, and to determine"/>
 <result pre="mainly represents the most sexually active population and therefore having" exact="chronic" post="exposure to sexually transmitted infections, including HPV. These results"/>
 <result pre="rate above the national proportion published in 2005 by the" exact="Central" post="Bureau of Censuses and Population Studies in Cameroon where"/>
 <result pre="rate of single women [15]. The median CD4 count was" exact="lower" post="in the frame of HIV-infection (354 versus 414 cells/mm3]"/>
 <result pre="CD4 levels could vary with different conditions, including but not" exact="limited" post="to stress, smoking, menstrual cycle, contraceptive pill, physical activity,"/>
 <result pre="in the Cameroonian context and need to be depict among" exact="cervical cancer" post="cases, especially in the frame of HIV-infection [14, 20]."/>
 <result pre="the Cameroonian context and need to be depict among cervical" exact="cancer" post="cases, especially in the frame of HIV-infection [14, 20]."/>
 <result pre="[14, 20]. Our findings are comparable to those found in" exact="Central" post="Africa Republic [21], which suggest a predominance of non-vaccine"/>
 <result pre="predictive effectiveness within the population of Cameroonin women. Co-infection with" exact="HIV infection" post="is a factor facilitating carcinogenesis associated with HR-HPV infections."/>
 <result pre="effectiveness within the population of Cameroonin women. Co-infection with HIV" exact="infection" post="is a factor facilitating carcinogenesis associated with HR-HPV infections."/>
 <result pre="Prospective studies have reported a higher incidence of HPV among" exact="HIV-positive" post="women compared to HIV-negative women [1, 14, 16]. Co-infections"/>
 <result pre="similar to previous reports [25]. Multi-infections are often associated with" exact="viral" post="persistence, especially if co-present with HPV 16. HIV is"/>
 <result pre="calls for the need to regularly test people with HPV" exact="infection" post="for HIV [27]. Younger age are at higher risk"/>
 <result pre="30, 31]. The lack of synergistic effect between the HIV" exact="viral" post="load and HPV-infection simply confirmed that HIV-infection interfers with"/>
 <result pre="and HPV-infection simply confirmed that HIV-infection interfers with HPV through" exact="immunodeficiency" post="induced by HIV, and not via a direct viral-viral"/>
 <result pre="status remains the independent factor associated with the risk of" exact="infection" post="with this high-risk oncogenic HPV (12 times higher risk),"/>
 <result pre="as the main independent factor associated with risk of HPV" exact="infection" post="among women, likely due to immunodeficiency. In other words,"/>
 <result pre="HIV condition) were found to be significantly associated with HPV" exact="infection" post="[36]. Our study has some limitations. For instance, the"/>
 <result pre="HIV-uninfected women was low; the presence of other comorbidities or" exact="infections" post="such as hepatitis B, hepatitis C, and tuberculosis, could"/>
 <result pre="low; the presence of other comorbidities or infections such as" exact="hepatitis" post="B, hepatitis C, and tuberculosis, could also affect the"/>
 <result pre="presence of other comorbidities or infections such as hepatitis B," exact="hepatitis" post="C, and tuberculosis, could also affect the immune status."/>
 <result pre="commonly known 16 and 18. Interestingly, in the event of" exact="HIV infection," post="the risk of HPV-infection becomes higher, favoured essentially by"/>
 <result pre="vaccine trials, would are needed to ensure effective prevention of" exact="cervical cancer" post="among HIV-infected women. Abbreviations AIDS Acquired immunodeficiency syndrome CD4"/>
 <result pre="trials, would are needed to ensure effective prevention of cervical" exact="cancer" post="among HIV-infected women. Abbreviations AIDS Acquired immunodeficiency syndrome CD4"/>
 <result pre="effective prevention of cervical cancer among HIV-infected women. Abbreviations AIDS" exact="Acquired" post="immunodeficiency syndrome CD4 Cluster of differentiation 4 CIRCB &quot;Chantal"/>
 <result pre="prevention of cervical cancer among HIV-infected women. Abbreviations AIDS Acquired" exact="immunodeficiency" post="syndrome CD4 Cluster of differentiation 4 CIRCB &quot;Chantal BIYA�?"/>
 <result pre="of cervical cancer among HIV-infected women. Abbreviations AIDS Acquired immunodeficiency" exact="syndrome" post="CD4 Cluster of differentiation 4 CIRCB &quot;Chantal BIYA�? International"/>
 <result pre="4 CIRCB &quot;Chantal BIYA�? International Reference Centre for research on" exact="HIV/AIDS" post="prevention and management DNA Deoxyribonucleic acid HIV Human Immunodeficiency"/>
 <result pre="on HIV/AIDS prevention and management DNA Deoxyribonucleic acid HIV Human" exact="Immunodeficiency" post="Virus; HPV Human papilloma virus HR-HPV High risk oncogenic"/>
 <result pre="management DNA Deoxyribonucleic acid HIV Human Immunodeficiency Virus; HPV Human" exact="papilloma" post="virus HR-HPV High risk oncogenic Human Immunodeficiency Virus LR-HPV"/>
 <result pre="Virus; HPV Human papilloma virus HR-HPV High risk oncogenic Human" exact="Immunodeficiency" post="Virus LR-HPV Low risk non-Human Immunodeficiency Virus PLHIV People"/>
 <result pre="High risk oncogenic Human Immunodeficiency Virus LR-HPV Low risk non-Human" exact="Immunodeficiency" post="Virus PLHIV People living with HIV RT-PCR Real-time polymerase"/>
 <result pre="6.Mathers CD, Loncar D. Projections of global mortalityand burden of" exact="disease" post="from 2002 to 2030. PLoS Med. 2006;3(11):e442. 10.1371/journal.pmed.0030442. 7.Amégbor"/>
 <result pre="to 2008: Epidemiological and Pathological Aspects of 5251 Cases. J" exact="Cancer" post="Epidemiol. 2011:2011 Disponible sur: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189592/. [cité 20 sept 2019]."/>
 <result pre="Disponible sur: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189592/. [cité 20 sept 2019]. 8.BestSRNiparkoKJPaiSIBiology of HPV" exact="Infection" post="and Immune Therapy for HPV-related Head and Neck CancersOtolaryngol"/>
 <result pre="10.Verma M, Erwin S, Abedi V, Hontecillas R, Hoops S," exact="Leber" post="A, et al. Modeling the Mechanisms by Which HIV-Associated"/>
 <result pre="2020]. 11.Ault KA. Epidemiology and Natural History of Human Papillomavirus" exact="Infections" post="in the Female Genital Tract. Infect Dis Obstet Gynecol."/>
 <result pre="Epidemiology and Natural History of Human Papillomavirus Infections in the" exact="Female" post="Genital Tract. Infect Dis Obstet Gynecol. 2006:2006 Disponible sur:"/>
 <result pre="2020]. 12.Mboumba BouassaR-SNodjikouambayeZASadjoliDAdawayeCPéréHVeyerDet al.High prevalence of cervical high-risk human papillomavirus" exact="infection" post="mostly covered by Gardasil-9 prophylactic vaccine in adult women"/>
 <result pre="human papillomavirus infection mostly covered by Gardasil-9 prophylactic vaccine in" exact="adult" post="women living in N’Djamena, ChadPLOS ONE2019146e021748610.1371/journal.pone.021748631158254 13.LyngeERygaardCBailletMV-PDuguéP-ASanderBBBondeJet al.Cervical cancer"/>
 <result pre="in adult women living in N’Djamena, ChadPLOS ONE2019146e021748610.1371/journal.pone.021748631158254 13.LyngeERygaardCBailletMV-PDuguéP-ASanderBBBondeJet al.Cervical" exact="cancer" post="screening at crossroadsAPMIS2014122866767310.1111/apm.1227925046198 14.Republic of Cameroon, Centre for the"/>
 <result pre="of cervical precancers among HIV-seropositive womenAm J Obstet Gynecol2015212560610.1016/j.ajog.2014.12.00325499260 17.Abu-RaddadLJPatnaikPKublinJGDual" exact="Infection" post="with HIV and Malaria Fuels the Spread of Both"/>
 <result pre="HIV-seropositive womenAm J Obstet Gynecol2015212560610.1016/j.ajog.2014.12.00325499260 17.Abu-RaddadLJPatnaikPKublinJGDual Infection with HIV and" exact="Malaria" post="Fuels the Spread of Both Diseases in Sub-Saharan AfricaScience200631458051603160610.1126/science.113233817158329"/>
 <result pre="Infection with HIV and Malaria Fuels the Spread of Both" exact="Diseases" post="in Sub-Saharan AfricaScience200631458051603160610.1126/science.113233817158329 18.Kabeyene OkonoCDescartesBMendimi NkodoMJSandoZAndersonDAmadouFEssame OyonoJLSerotypes of high"/>
 <result pre="lesionsHealth Sci2015162015 19.AlbertJAbrahamssonBNagyKAureliusEGainesHNyströmGet al.Rapid development of isolate-specific neutralizing antibodies after" exact="primary" post="HIV-1 infection and consequent emergence of virus variants which"/>
 <result pre="19.AlbertJAbrahamssonBNagyKAureliusEGainesHNyströmGet al.Rapid development of isolate-specific neutralizing antibodies after primary HIV-1" exact="infection" post="and consequent emergence of virus variants which resist neutralization"/>
 <result pre="16 and 18 prevalence among women with normal cervical cytology" exact="and neoplasia" post="in Cameroon: a systematic review. 2017. 25.PerronsCJelleyRKleterBQuintWBrinkNDetection of persistent"/>
 <result pre="systematic review. 2017. 25.PerronsCJelleyRKleterBQuintWBrinkNDetection of persistent high risk human papillomavirus" exact="infections" post="with hybrid capture II and SPF10/LiPAJ Clin Virol200532427828510.1016/j.jcv.2004.08.00915780805 26.MassadLSSilverbergMJSpringerGMinkoffHHessolNPalefskyJMet"/>
 <result pre="26.MassadLSSilverbergMJSpringerGMinkoffHHessolNPalefskyJMet al.Effect of antiretroviral therapy on the incidence of genital" exact="warts" post="and vulvar neoplasia among women with the human immunodeficiency"/>
 <result pre="genital warts and vulvar neoplasia among women with the human" exact="immunodeficiency" post="virusAm J Obstet Gynecol200419051241124810.1016/j.ajog.2003.12.03715167825 27.pubmeddev, al A-RC et. [Human"/>
 <result pre="papillomavirus carcinogenesis--role of parity, oral contraceptives, and tobacco smokingJ Natl" exact="Cancer" post="Inst Monogr200331202810.1093/oxfordjournals.jncimonographs.a003477 29.Soto-De Leon S, Camargo M, Sanchez R,"/>
 <result pre="M, Perez-Prados A, Purroy A, et al. Distribution Patterns of" exact="Infection" post="with Multiple Types of Human Papillomaviruses and Their Association"/>
 <result pre="A, Purroy A, et al. Distribution Patterns of Infection with" exact="Multiple" post="Types of Human Papillomaviruses and Their Association with Risk"/>
 <result pre="with HPV/HIV co-infectionMedicine (Baltimore)20189714e954510.1097/MD.000000000000954529620669 32.CastellsaguéXPaavonenJJaisamrarnUWheelerCMSkinnerSRLehtinenMet al.Risk of first cervical HPV" exact="infection" post="and pre-cancerous lesions after onset of sexual activity: analysis"/>
 <result pre="Jianghong D. Prevalence and risk factors of anal human papillomavirus" exact="infection" post="among HIV-negative men who have sex with men in"/>
 <result pre="China. PLoS One. 2017;12(11):e0187928. 10.1371/journal.pone.0187928. eCollection 2017. 34.van der BurgSHPalefskyJMHuman" exact="immunodeficiency" post="virus and human papilloma virus - why HPV-induced lesions"/>
 <result pre="10.1371/journal.pone.0187928. eCollection 2017. 34.van der BurgSHPalefskyJMHuman immunodeficiency virus and human" exact="papilloma" post="virus - why HPV-induced lesions do not spontaneously resolve"/>
 <result pre="Transl Med2009710810.1186/1479-5876-7-10820021658 35.PikettyCDarraghTMDa CostaMBrunevalPHeardIKazatchkineMDet al.High prevalence of anal human papillomavirus" exact="infection" post="and anal cancer precursors among HIV-infected persons in the"/>
 <result pre="35.PikettyCDarraghTMDa CostaMBrunevalPHeardIKazatchkineMDet al.High prevalence of anal human papillomavirus infection and" exact="anal cancer" post="precursors among HIV-infected persons in the absence of anal"/>
 <result pre="CostaMBrunevalPHeardIKazatchkineMDet al.High prevalence of anal human papillomavirus infection and anal" exact="cancer" post="precursors among HIV-infected persons in the absence of anal"/>
 <result pre="infection and anal cancer precursors among HIV-infected persons in the" exact="absence of" post="anal intercourseAnn Intern Med2003138645345910.7326/0003-4819-138-6-200303180-0000812639077 36.TartagliaEFalascaKVecchietJSabuscoGPPiccianoGDi MarcoRet al.Prevalence of HPV"/>
 <result pre="of anal intercourseAnn Intern Med2003138645345910.7326/0003-4819-138-6-200303180-0000812639077 36.TartagliaEFalascaKVecchietJSabuscoGPPiccianoGDi MarcoRet al.Prevalence of HPV" exact="infection" post="among HIV-positive and HIV-negative women in Central/Eastern Italy: Strategies"/>
 <result pre="intercourseAnn Intern Med2003138645345910.7326/0003-4819-138-6-200303180-0000812639077 36.TartagliaEFalascaKVecchietJSabuscoGPPiccianoGDi MarcoRet al.Prevalence of HPV infection among" exact="HIV-positive" post="and HIV-negative women in Central/Eastern Italy: Strategies of preventionOncol"/>
</results>
